Pharmacogenetic testing (PGx) of polymorphisms that alter the expression of genes asso- ciated with the distribution and response to antipsychotics (APs) can replace the "trial and error" method in AP dosage adjustment and reduce the risk of AP-induced adverse drug reactions (ADRs). This narrative review demonstrates the growing commercial interest in the pharmacogenomics and pharmaco-economics of PGх. However, the significant heterogeneity of pharmacogenetic panels and the lack of unified interpretation standards substantially hinder the implementation of PGх as an advanced tool in personalized psychiatry. The conducted review demonstrates not only techno- logical and commercial progress in the field of PGх for APs but also a complex of interrelated problems that require resolution for the successful translation of this method from the realms of scientific research and commercial services into the routine clinical practice. Although the develop- ment of PGх for identifying at risk patient groups aligns with Russia's new healthcare development strategy, numerous barriers impede its implementation into psychiatric practice. One such barrier is the lack of data on the convergence of pharmacogenomics and pharmacoeconomics of APs. Re- moving this barrier can facilitate the development and real-world clinical implementation of diagnostic pharmacogenetic test systems as a key to a new era of personalized, cost-effective, and safe therapy for mental disorders.